Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21323530 | 0.85 | ADORA2A (0.32) | NOS1NOS2ADORA2A | |
| SCHEMBL3625374 | 0.84 | GABRA1 (0.44) | GABRA1GABRB2NOS1NOS2NOS3 | |
| SCHEMBL24453820 | 0.84 | GABRA1 (0.39) | GABRA1GABRB2NOS1NOS2NOS3 | |
| SCHEMBL15316714 | 0.82 | GABRA1 (0.34) | GABRA1GABRB2NOS1NOS2NOS3 | |
| SCHEMBL1581851 | 0.81 | KCNH2 (0.36) | NOS1NOS2ADORA2AKCNH2CHRNA7 | |
| SCHEMBL2614966 | 0.81 | KDM4E (0.46) | GABRA1GABRB2NOS1NOS2NOS3 | |
| SCHEMBL31481285 | 0.81 | KCNH2 (0.36) | NOS1NOS2ADORA2AKCNH2CHRNA7 | |
| SCHEMBL12120627 | 0.80 | SYK (0.40) | NOS1NOS2NOS3ADORA2AESR1 | |
| SCHEMBL4051420 | 0.79 | CCR1 (0.40) | NOS1NOS2ADORA2AKCNH2CHRNA7 | |
| SCHEMBL19363978 | 0.79 | ADORA2A (0.34) | NOS1NOS2ADORA2AKCNH2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
| US-20200345804-A1 | NOVEL AGENTS TARGETING INHIBITOR OF APOPTOSIS PROTEINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-11-05 | — | — | US | disclosed |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-14 | — | — | US | disclosed |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9809590-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809590-B2 | Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-9650341-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-05-16 | — | — | US | disclosed |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2010075200-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010007114-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007116-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | GABRA1 4113/4885GABRB2 3376/4885NOS1 3045/4885 |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | GABRA1 11/4885GABRB2 7/4885NOS1 2871/4885 |
| US-20110313156-A1 | HETEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | PDK2, PDK4, CCNH | GABRA1 4648/4885GABRB2 4654/4885NOS1 1884/4885 |
| US-20180086758-A1 | SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | LTK, MUSK, FGFR1 | GABRA1 2069/4885GABRB2 2669/4885NOS1 1915/4885 |
| US-20200345804-A1 | NOVEL AGENTS TARGETING INHIBITOR OF APOPTOSIS PROTEINS | XIAP, BIRC2, BIRC5 | GABRA1 4221/4885GABRB2 3662/4885NOS1 4313/4885 |
| US-20110269958-A1 | PYRIDONS AS PDK1 INHIBITORS | PDK1, PDK2, PDK4 | GABRA1 3616/4885GABRB2 3443/4885NOS1 2078/4885 |
| US-20120258952-A1 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors | AFF1, FLI1, F3 | GABRA1 2192/4885GABRB2 3377/4885NOS1 376/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | GABRA1 4113/4885GABRB2 3376/4885NOS1 3045/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | GABRA1 1353/4885GABRB2 1149/4885NOS1 2128/4885 |
| US-20120101103-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | PTGDR2, PTGDR, HRH2 | GABRA1 2524/4885GABRB2 2322/4885NOS1 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.